دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Immunosuppressive Therapy and Risk of COVID-19 Infection in Patients With Inflammatory Bowel Diseases
Kristin E Burke, MD, MPH, Bharati Kochar, MD, MSCR, Jessica R Allegretti, MD, MPH, Rachel W Winter, MD, MPH, Paul Lochhead, MBChB, PhD
doi : 10.1093/ibd/izaa278
Inflammatory Bowel Diseases, Volume 27, Issue 2, February 2021, Pages 155–161
The effect of immunosuppressive treatment for immune-mediated diseases on risk of the novel coronavirus disease 2019 (COVID-19) has not been established. We aimed to define the effect of targeted biologic and immunomodulator therapy on risk of COVID-19 in a multi-institutional cohort of patients with inflammatory bowel disease (IBD).
Cigarette Smoking, Coffee Consumption, Alcohol Intake, and Risk of Crohn’s Disease and Ulcerative Colitis: A Mendelian Randomization Study
Andrea N Georgiou, PhD, Georgios Ntritsos, PhD, Nikos Papadimitriou, PhD, Niki Dimou, PhD, Evangelos Evangelou, PhD
doi : 10.1093/ibd/izaa152
Inflammatory Bowel Diseases, Volume 27, Issue 2, February 2021, Pages 162–168
Crohn’s disease (CD) and ulcerative colitis (UC) are widely associated with smoking in epidemiological studies, whereas there are conflicting results for the association between CD and UC for both coffee and alcohol consumption. Herein, we aimed to investigate whether cigarette smoking and alcohol and coffee consumption are causally associated with either CD or UC.
Circulating Leptin Levels as a Potential Biomarker in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis
Larissa Gabriela Ferreira de Carvalho, MD, William Gustavo Lima, MD, Luiz Gonzaga Vaz Coelho, PhD, Valbert Nascimento Cardoso, PhD, Simone Od?lia Antunes Fernandes, PhD
doi : 10.1093/ibd/izaa037
Inflammatory Bowel Diseases, Volume 27, Issue 2, February 2021, Pages 169–181
The differential diagnosis of inflammatory bowel diseases (IBDs) between Crohn’s disease (CD) and ulcerative colitis (UC) is important for designing an effective therapeutic regimen. However, without any adequate gold standard method for differential diagnosis currently, therapeutic design remains a major challenge in clinical practice. In this context, recent studies have showed that circulating leptin stands out as a potential biomarker for the categorization of IBDs. Thus, we aimed to summarize the current understanding of the prognostic and diagnostic value of serum leptin in patients with IBDs.
The SPOSIB SB2 Sicilian Cohort: Safety and Effectiveness of Infliximab Biosimilar SB2 in Inflammatory Bowel Diseases, Including Multiple Switches
Fabio Salvatore Macaluso, MD, Walter Fries, MD, Anna Viola, MD, Andrea Centritto, MD, Maria Cappello, MD
doi : 10.1093/ibd/izaa036
Inflammatory Bowel Diseases, Volume 27, Issue 2, February 2021, Pages 182–189
No data on the recently introduced infliximab (IFX) biosimilar SB2 in inflammatory bowel disease (IBD) are available.
Association Between Change in Inflammatory Aspects of Diet and Change in IBD-related Inflammation and Symptoms Over 1 Year: The Manitoba Living With IBD Study
Kathy Vagianos, RD, MSc, Leigh Anne Shafer, PhD, Kelcie Witges, MPH, Laura E Targownik, MD, Clove Haviva, PhD
doi : 10.1093/ibd/izaa052
Inflammatory Bowel Diseases, Volume 27, Issue 2, February 2021, Pages 190–202
We aimed to investigate (1) the stability of inflammatory aspects of diet over 1 year among persons with inflammatory bowel disease (IBD) and (2) the impact of change in diet on changes in inflammation and IBD symptoms over 1 year.
Cumulative Histologic Inflammation Predicts Colorectal Neoplasia in Ulcerative Colitis: A Validation Study
Olivia V Yvellez, Victoria Rai, Philip H Sossenheimer, John Hart, MD, Jerrold R Turner, MD, PhD
doi : 10.1093/ibd/izaa047
Inflammatory Bowel Diseases, Volume 27, Issue 2, February 2021, Pages 203–206
Chronic inflammation in ulcerative colitis (UC) is associated with the development of colorectal neoplasia (CRN). A group at St. Mark’s Hospital reported a novel cumulative inflammatory index that predicted the development of CRN in UC patients that we validated with an independent, well-described, matched, case-controlled cohort from the University of Chicago.
Endoscopic and Histological Assessment, Correlation, and Relapse in Clinically Quiescent Ulcerative Colitis (MARQUEE)
Mark T Osterman, MD, MSCE, Frank I Scott, MD, MSCE, Franz F Fogt, MD, Erin D Gilroy, Susan Parrott, BSN
doi : 10.1093/ibd/izaa048
Inflammatory Bowel Diseases, Volume 27, Issue 2, February 2021, Pages 207–214
It is difficult to predict relapse in quiescent ulcerative colitis (UC), but newer endoscopic and histological indices could improve this. This study aimed to determine in UC patients in clinical remission (1) the prevalence of active endoscopic and histological disease; (2) the correlation between endoscopic and histological scores; and (3) the predictive power of these scores for clinical relapse.
The Natural History, Treatments, and Outcomes of Portal Vein Thrombosis in Patients With Inflammatory Bowel Disease
Leonard Naymagon, MD, Douglas Tremblay, MD, Nicole Zubizarreta, MPH, Erin Moshier, MS, Steven Naymagon, MD
doi : 10.1093/ibd/izaa053
Inflammatory Bowel Diseases, Volume 27, Issue 2, February 2021, Pages 215–223
Portal vein thrombosis (PVT) is a poorly described complication of inflammatory bowel disease (IBD). We sought to better characterize presentations, compare treatments, and assess outcomes in IBD-related PVT.
Distribution and Cytokine Profile of Peripheral B Cell Subsets Is Perturbed in Pediatric IBD and Partially Restored During a Successful IFX Therapy
Alexander Schnell, MD, Benedikt Schwarz, MD, Mandy Wahlbuhl, PhD, Ida Allabauer, Merlin Hess, MD
doi : 10.1093/ibd/izaa054
Inflammatory Bowel Diseases, Volume 27, Issue 2, February 2021, Pages 224–235
The role of B cells in inflammatory bowel disease (IBD) is ambiguous, as B cells may have both pathogenic and protective functions in IBD. We studied B cell subsets before and after initiation of an anti-tumor necrosis factor alpha (anti-TNF?) therapy in pediatric IBD. The aim of the study was to examine the behavior of B cells in pediatric IBD patients undergoing an anti-TNF? therapy and, more specifically, to clarify their association with a successful or an unsuccessful infliximab (IFX) treatment.
Daily Aspirin Use Does Not Impact Clinical Outcomes in Patients With Inflammatory Bowel Disease
Parita Patel, MD, Guimin Gao, PhD, George Gulotta, MS, Sushila Dalal, MD, Russell D Cohen, MD
doi : 10.1093/ibd/izaa060
Inflammatory Bowel Diseases, Volume 27, Issue 2, February 2021, Pages 236–241
Although several studies have associated the use of nonsteroidal anti-inflammatory drugs with disease flares in patients with inflammatory bowel disease (IBD), little is known about the impact of daily aspirin use on clinical outcomes in patients with IBD.
Mast Cell Tryptase Promotes Inflammatory Bowel Disease–Induced Intestinal Fibrosis
Bin Liu, MD, Mu-Qing Yang, MD, PhD, Tian-Yu Yu, MD, Yang-Yang Yin, MD, Ying Liu, MD
doi : 10.1093/ibd/izaa125
Inflammatory Bowel Diseases, Volume 27, Issue 2, February 2021, Pages 242–255
Intestinal fibrosis is the final pathological outcome of chronic intestinal inflammation without specific therapeutic drugs, which leads to ileus and surgical intervention. Intestinal fibrosis is characterized by excessive deposition of extracellular matrix (ECM). The role of mast cells (MCs), which are members of the sentinel immune cell population, is unknown in intestinal fibrosis.
Colonoids From Patients With Pediatric Inflammatory Bowel Disease Exhibit Decreased Growth Associated With Inflammation Severity and Durable Upregulation of Antigen Presentation Genes
Judith R Kelsen, MD, Noor Dawany, PhD, Maire A Conrad, MD, Tatiana A Karakasheva, PhD, Kelly Maurer, MS
doi : 10.1093/ibd/izaa145
Inflammatory Bowel Diseases, Volume 27, Issue 2, February 2021, Pages 256–267
Defining epithelial cell contributions to inflammatory bowel disease (IBD) is essential for the development of much needed therapies for barrier repair. Children with very early onset (VEO)-IBD have more extensive, severe, and refractory disease than older children and adults with IBD and, in some cases, have defective barrier function. We therefore evaluated functional and transcriptomic differences between pediatric IBD (VEO and older onset) and non-IBD epithelium using 3-dimensional, biopsy-derived organoids.
Profiling of Human Circulating Dendritic Cells and Monocyte Subsets Discriminates Between Type and Mucosal Status in Patients With Inflammatory Bowel Disease
Lorena Ortega Moreno, PhD, Samuel Fern?ndez-Tomé, PhD, Mar?a Chaparro, MD, PhD, Alicia C Marin, MSc, Irene Mora-Gutiérrez
doi : 10.1093/ibd/izaa151
Inflammatory Bowel Diseases, Volume 27, Issue 2, February 2021, Pages 268–274
Intestinal dendritic cells (DC) and macrophages drive disease progression in patients with inflammatory bowel disease (IBD). We aimed to characterize the activation and homing profile of human circulating DC and monocyte subsets in healthy control patients (CP) and IBD patients.
A Systematic Review on Cost-effectiveness Analyses of Therapeutic Drug Monitoring for Patients with Inflammatory Bowel Disease: From Immunosuppressive to Anti-TNF Therapy
Jiaqi Yao, MPhil, Xinchan Jiang, MPhil, Joyce H S You, PharmD
doi : 10.1093/ibd/izaa073
Inflammatory Bowel Diseases, Volume 27, Issue 2, February 2021, Pages 275–282
There is a growing body of primary evidence on the cost-effectiveness of applying therapeutic drug monitoring (TDM) for inflammatory bowel disease (IBD) management with various drug therapies and strategies.
Endocytosis of Intestinal Tight Junction Proteins: In Time and Space
Prashant Nighot, MVSc, PhD, Thomas Ma, MD, PhD
doi : 10.1093/ibd/izaa141
Inflammatory Bowel Diseases, Volume 27, Issue 2, February 2021, Pages 283–290
Eukaryotic cells take up macromolecules and particles from the surrounding milieu and also internalize membrane proteins via a precise process of endocytosis. The role of endocytosis in diverse physiological processes such as cell adhesion, cell signaling, tissue remodeling, and healing is well recognized. The epithelial tight junctions (TJs), present at the apical lateral membrane, play a key role in cell adhesion and regulation of paracellular pathway. These vital functions of the TJ are achieved through the dynamic regulation of the presence of pore and barrier-forming proteins within the TJ complex on the plasma membrane. In response to various intracellular and extracellular clues, the TJ complexes are actively regulated by intracellular trafficking. The intracellular trafficking consists of endocytosis and recycling cargos to the plasma membrane or targeting them to the lysosomes for degradation. Increased intestinal TJ permeability is a pathological factor in inflammatory bowel disease (IBD), and the TJ permeability could be increased due to the altered endocytosis or recycling of TJ proteins. This review discusses the current information on endocytosis of intestinal epithelial TJ proteins. The knowledge of the endocytic regulation of the epithelial TJ barrier will provide further understanding of pathogenesis and potential targets for IBD and a wide variety of human disease conditions.
Should We Be Screening for SARS-CoV-2 in IBD Patients Before Initiation of Biologic Therapy?
Jana G Hashash, MD, MSc, Suha Jabak, MD, Fadi F Francis, MD, Miguel Regueiro, MD
doi : 10.1093/ibd/izaa173
Inflammatory Bowel Diseases, Volume 27, Issue 2, February 2021, Pages 291–294
Before initiation of biologic therapy, current guidelines recommend screening for hepatitis B virus, human immunodeficiency virus, and latent mycobacterium tuberculosis infections.1,2 It is also recommended to screen for susceptibility to primary varicella zoster virus (VZV) infection, and it is suggested to check for hepatitis C virus infection. With the current coronavirus disease 2019 (COVID-19) pandemic and the high prevalence of asymptomatic infected individuals, the question is raised as to whether or not we need to check for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection before initiation of biological therapy in inflammatory bowel disease (IBD) patients.
Gut Microbiota-Mediated Pleiotropic Effects of Fucose Can Improve Inflammatory Bowel Disease by Modulating Bile Acid Metabolism and Enhancing Propionate Production
Stanislav Sitkin, MD, PhD, Timur Vakhitov, PhD, Svetlana Kononova, PhD, Maria Skalinskaya, PhD, Juris Pokrotnieks, MD, PhD
doi : 10.1093/ibd/izaa233
Inflammatory Bowel Diseases, Volume 27, Issue 2, February 2021, Pages e10–e11
We read with great interest the manuscript by Ke et al,1 who showed that fucose ameliorates dextran sodium sulfate colitis by restoring the cross-talk between bile acids (BAs) and gut microbiota. The authors showed for the first time that fucose can beneficially alter dysregulated BA metabolism by modulating microbiota and restoring the gut microbial ecosystem, although the exact mechanism remains elusive.
Reply to the Letter: Gut Microbiota-mediated Pleiotropic Effects of Fucose Can Improve Inflammatory Bowel Disease by Modulating Bile Acid Metabolism and Enhancing Propionate Production
Jun Ke, PhD, Ruohang He, PhD, Xiaohua Hou, PhD
doi : 10.1093/ibd/izaa234
Inflammatory Bowel Diseases, Volume 27, Issue 2, February 2021, Page e12
We greatly appreciate the interest and insightful comments of Dr. Sitkin and colleagues regarding our article in which we showed that fucose can ameliorate dextran sodium sulfate (DSS)-induced colitis through modulation of gut microbiota and bile acid metabolism.
Tofacitinib for the Treatment of Ulcerative Colitis, Alopecia Universalis, and Atopic Dermatitis: One Drug, Three Diseases
Sailish Honap, MBChB, MRCP, Hannah Cookson, MBChB, MRCP, Esha Sharma, MPharm, Mark A Samaan, MD, Peter M Irving, MD
doi : 10.1093/ibd/izaa243
Inflammatory Bowel Diseases, Volume 27, Issue 2, February 2021, Pages e13–e14
Tofacitinib is the first Janus kinase (JAK) inhibitor licensed for the treatment of ulcerative colitis (UC), rheumatoid arthritis, and psoriatic arthritis. Promising outcomes have also been reported in controlled and uncontrolled studies for other immune-mediated inflammatory diseases (IMIDs).1 We report the first case of tofacitinib successfully treating 3 coexisting IMIDs: UC, severe atopic dermatitis (AD), and alopecia universalis (AU).
Cutaneous Vasculitis Associated With Vedolizumab in Ulcerative Colitis
Lucas Fernandes de Freitas, MD, Marley Ribeiro Feitosa, MD, PhD, Omar Féres, MD, PhD, Rogério Serafim Parra, MD, PhD
doi : 10.1093/ibd/izaa255
Inflammatory Bowel Diseases, Volume 27, Issue 2, February 2021, Pages e15–e17
Cutaneous vasculitis (CV) is a rare inflammation of the vessel walls that affects the skin. It has been reported in patients with inflammatory bowel disease (IBD), mainly in patients with Crohn’s disease (CD) and patients undergoing anti-tumor necrosis factor alpha therapy.1 Vedolizumab (VDZ) is a humanized monoclonal antibody against integrin ??4??7 approved to treat patients with moderate to severe IBD (both ulcerative colitis [UC] and CD), with few skin adverse effects reported.2 Studies have reported CV in 2 patients with CD treated with VDZ.3, 4 We report the first case...
Is There Really a Direct Relationship Between IBD and Anxiety/Depression, or Could Any Chronic Disease Have These Manifestations?
Carlos Henrique Marques dos Santos, MD, PhD, Amanda Cristine Alcântara Galindo, MD, B?rbara Alencar da Silva, MD, Camila Rodrigues Dantas, MD, Isadora Albuquerque de Ara?jo Guilherme, MD
doi : 10.1093/ibd/izaa259
Inflammatory Bowel Diseases, Volume 27, Issue 2, February 2021, Pages e18–e19
Inflammatory bowel disease (IBD) has a high probability of affecting mental health, possibly because of its chronic and progressive nature, which negatively contributes to the quality of life.1, 2 However, the question that arises in this situation is whether a direct relationship between IBD and emotional disorders exists or whether a chronic disease in and of itself could cause such disorders.
Patient with Fistulizing Crohn’s Disease with Nonresponse to Infliximab Subsequently Responds to Infliximab After Short-term Addition of Tacrolimus
Scott Lee, MD, Kindra Clark-Snustad, DNP
doi : 10.1093/ibd/izaa260
Inflammatory Bowel Diseases, Volume 27, Issue 2, February 2021, Pages e20–e22
Infliximab is a tumor necrosis factor (TNF) antagonist effective for Crohn’s disease (CD), with variable pharmacokinetics (pK) and increased drug clearance in active disease and hypoalbuminemia. Tacrolimus is a calcineurin inhibitor and nonbiologic immunosuppressant that has been studied in CD 1, 2. We hypothesized that in patients with nonmechanistic failure of infliximab (low or absent drug level without antidrug antibodies), the addition of tacrolimus may reduce inflammatory burden, improve hypoalbuminemia, alter the pK and clearance of the biologic, and result in therapeutic biologic drug levels. We hypothesized that after achieving therapeutic biologic drug levels, we could discontinue tacrolimus and maintain response with the biologic
The Challenge of Treating Pyoderma Gangrenosum in a Patient With Crohn Disease Based on Poor Scientific Evidence
Carlos Henrique Marques dos Santos, MD, PhD, Gabrielli Avelar Koga, MD
doi : 10.1093/ibd/izaa264
Inflammatory Bowel Diseases, Volume 27, Issue 2, February 2021, Pages e23–e24
Some cases of pyoderma gangrenosum can be extremely challenging, especially because there is no robust evidence regarding the best therapeutic options. We assisted a female patient aged 44 years who was previously colostomized after resection of a sigmoid tumor and presented with low digestive hemorrhage. A colonoscopy was performed (Supplementary Fig. 1) showing moderate colitis in the excluded colon. She reported Crohn disease with no treatment, so we started a mesalamine enema, which yielded a good response.
